It was reported that the p38-MAPK pathway contributed to the phosphorylation of Tau protein and synaptic damage [42, 43], and a clinical study showed that the p38α-MAPK inhibitor could improve memory function in AD patients [44]. This evidence concerns the gene MAPT and Alzheimer disease.